Drugs Containing Excipient (Inactive Ingredient) ZINC OXIDE

Generic drugs containing ZINC OXIDE excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	insulin lispro	0002-7511	ZINC OXIDE
Eli Lilly and Company	insulin lispro	0002-7512	ZINC OXIDE
Eli Lilly and Company	insulin glargine	0002-7715	ZINC OXIDE
Eli Lilly and Company	insulin lispro-aabc	0002-7728	ZINC OXIDE

Zinc Oxide Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: August 6, 2026

Zinc oxide is a mature, low-cost inorganic pharmaceutical material with stable demand in topical, dermatological, wound-care, oral-care, and protective formulations. Its pharmaceutical-excipient market is fragmented and difficult to isolate from the much larger industrial zinc oxide market. Revenue growth is likely to remain modest, driven by volume expansion, regional manufacturing shifts, higher regulatory costs, and premiums for controlled particle size, low heavy-metal content, GMP production, and documentation. Commodity zinc prices and energy costs remain the principal financial variables.

The strongest commercial position is held by suppliers that can provide pharmaceutical-grade zinc oxide with consistent morphology, validated impurity controls, reliable documentation, and regulatory support. Basic zinc oxide has limited standalone patent protection. Commercial barriers arise primarily from qualification, formulation know-how, manufacturing controls, customer switching costs, and regulatory files.

What is zinc oxide used for in pharmaceutical formulations?

Zinc oxide is used as both an active pharmaceutical ingredient and an excipient, depending on the product and jurisdiction. Its most established applications are topical.

Application	Pharmaceutical role	Commercial relevance
Diaper-rash creams	Skin protectant active	High-volume, price-sensitive
Dermatological ointments	Skin protectant, astringent, opacifier	Stable generic and branded demand
Sunscreens	UV filter active	High-value formulation use; regulatory scrutiny
Wound-care products	Protective and soothing agent	Moderate growth in chronic-care markets
Calamine-type products	Skin-protective ingredient	Mature market
Dental and oral-care products	Functional mineral ingredient	Smaller pharmaceutical-excipient segment
Tablets and capsules	Colorant, absorbent, or functional additive in selected products	Limited relative to topical use
Veterinary pharmaceuticals	Topical protectant and barrier ingredient	Expands the addressable market

In the United States, zinc oxide is recognized in FDA OTC frameworks for skin-protectant products and is also used in sunscreen products under the FDA sunscreen regulatory framework (U.S. Food and Drug Administration [FDA], 2024a, 2024b). Its use as an excipient remains product-specific. A supplier cannot assume that an ingredient’s monograph or prior use establishes acceptance for every route, dosage form, particle size, or nanomaterial specification.

How large is the pharmaceutical zinc oxide excipient market?

The pharmaceutical-only market is not reported consistently by public market studies. Most commercial reports combine pharmaceutical zinc oxide with cosmetics, personal care, rubber, ceramics, paints, animal nutrition, electronics, and industrial applications. Those combined markets are substantially larger than the pharmaceutical-excipient segment.

The pharmaceutical segment is best characterized as:

• A small share of global zinc oxide consumption.
• A higher-margin segment than standard industrial zinc oxide.
• A specification-driven market rather than a capacity-driven market.
• Concentrated in topical and dermatological products.
• Exposed to generic-drug pricing and private-label competition.
• Less sensitive to innovation than specialty excipients such as lipid nanoparticles, polymers, or inhalation-grade materials.

The financial trajectory is therefore likely to differ from the overall zinc oxide market. Industrial zinc oxide revenue can move sharply with zinc prices, construction demand, tire production, ceramics, and energy costs. Pharmaceutical-grade revenue typically has lower price volatility because customers qualify suppliers and formulations over long periods. Volume growth remains moderate, while price increases can be passed through selectively.

What is the financial trajectory for pharmaceutical-grade zinc oxide?

The base-case trajectory is low- to mid-single-digit annual revenue growth over a medium-term planning horizon, with earnings determined more by product mix and input costs than by pharmaceutical demand alone.

Period	Expected market condition	Financial effect
Near term	Stable topical demand; volatile zinc and energy costs	Revenue resilient; margins exposed to input prices
Medium term	Growth in dermatology, wound care, sunscreen, and emerging-market manufacturing	Moderate volume expansion
Longer term	Greater demand for traceable, low-impurity, controlled-particle-size material	Premium-grade margins improve; commodity margins compress

Revenue drivers

The main revenue drivers are:

1. Growth in dermatology and wound-care products.
2. Expansion of generic and private-label topical products.
3. Sunscreen demand, subject to regional regulatory requirements.
4. Increased use of high-purity and controlled-morphology grades.
5. Supplier qualification in India, China, Southeast Asia, Latin America, and the Middle East.
6. Contract manufacturing and outsourced pharmaceutical production.

Margin drivers

Pharmaceutical-grade zinc oxide generally commands a premium over industrial grades because suppliers must maintain batch consistency, traceability, validated cleaning, change-control procedures, analytical testing, and regulatory documentation. The premium is strongest for:

• Low lead, cadmium, arsenic, mercury, and other specified impurities.
• Defined particle-size distribution.
• Low microbial burden.
• Controlled surface area and morphology.
• GMP-compatible manufacturing.
• Nitrosamine, elemental-impurity, and extractables documentation where relevant.
• DMF or equivalent regulatory support, when available.

The margin ceiling remains limited by substitution and customer price sensitivity. In many topical products, zinc oxide is a relatively inexpensive component of the finished formulation. Buyers can switch among qualified suppliers if the replacement material meets the same compendial, physical, and regulatory specifications.

Which companies supply pharmaceutical-grade zinc oxide?

The supply base includes specialty zinc oxide manufacturers, chemical companies, and regional pharmaceutical-material suppliers. Examples of major zinc oxide producers with broad industrial or specialty portfolios include EverZinc, Zochem, U.S. Zinc, Grillo-Werke, and other regional producers. Supplier qualification must be assessed at the individual manufacturing site and grade level; an industrial zinc oxide producer is not automatically a pharmaceutical excipient supplier.

Supplier characteristic	Strategic value
Integrated zinc sourcing	Reduces exposure to third-party raw-material disruptions
Multiple production sites	Improves continuity and geographic coverage
Dedicated pharmaceutical grade	Supports higher price and customer retention
GMP or pharmaceutical quality systems	Reduces customer qualification risk
Particle engineering capability	Enables formulation differentiation
Regulatory support	Shortens customer filing and variation work
Regional warehousing	Reduces lead times and inventory requirements

The competitive market has two tiers. Large producers compete on supply reliability, quality systems, and global coverage. Smaller producers compete on regional responsiveness, custom specifications, and lower conversion costs. Distributors remain relevant where pharmaceutical customers purchase modest volumes and require local technical support.

How do zinc prices affect pharmaceutical excipient margins?

Zinc oxide is manufactured from zinc metal or zinc-bearing feedstocks, so zinc prices are the largest raw-material exposure. Energy, oxygen, labor, freight, packaging, and environmental-compliance costs affect conversion margins.

The pricing structure often includes:

• A zinc-linked raw-material component.
• A conversion charge.
• Packaging and logistics.
• Quality and documentation premiums.
• Special testing or custom particle-size charges.

This structure allows producers to pass through part of the zinc-price movement. The timing of pass-through creates working-capital and margin risk. Producers with long-term contracts and delayed price adjustments can experience temporary margin compression during rapid zinc-price increases. Producers selling on spot or indexed contracts have better protection but may face customer resistance during declining market conditions.

What regulatory requirements apply to zinc oxide as a pharmaceutical excipient?

Zinc oxide is subject to route-specific and product-specific controls. The regulatory position depends on whether it is classified as an active ingredient, inactive ingredient, color additive, or functional formulation component.

United States

Relevant FDA sources include:

• FDA Inactive Ingredient Database, which records prior use by route and dosage form (FDA, 2024c).
• USP-NF Zinc Oxide monograph.
• OTC skin-protectant requirements under 21 C.F.R. Part 347.
• Sunscreen regulatory requirements under 21 C.F.R. Part 352 and related FDA guidance.
• Current good manufacturing practice requirements under 21 C.F.R. Parts 210 and 211.

An excipient supplier’s commercial value increases when it provides a complete package covering the compendial monograph, specifications, safety data, impurity profile, elemental analysis, residual solvents where applicable, microbial controls, and change-control commitments.

European Union

In the European Union, zinc oxide may be subject to European Pharmacopoeia requirements, product-specific marketing authorization review, cosmetic restrictions, and nanomaterial rules where nanoscale material is used. The European Medicines Agency does not provide a single centralized approval for all pharmaceutical excipients. Finished-product sponsors remain responsible for demonstrating suitability, quality, and safety.

Asia-Pacific and other markets

India and China are important production and consumption centers. Local pharmacopeial requirements, import controls, GMP inspections, and documentation standards can differ from those in the United States and Europe. Suppliers targeting multinational customers typically maintain dual or multi-compendial testing capability.

What patents protect zinc oxide pharmaceutical formulations?

Basic zinc oxide is an old inorganic compound and is not protected by a modern composition-of-matter patent. The principal intellectual-property opportunities involve:

• Particle-size engineering.
• Nanostructured zinc oxide.
• Surface coatings and dispersants.
• Sunscreen formulations.
• Wound-healing compositions.
• Mucoadhesive or controlled-release systems.
• Combination products with antimicrobials, corticosteroids, antifungals, or barrier polymers.
• Manufacturing methods that control morphology, purity, or dispersion.
• Packaging systems that improve stability or reduce aggregation.

Formulation patents may protect a specific concentration range, excipient combination, particle-size distribution, coating, dosage form, or method of use. Their value depends on claim scope, prosecution history, enforceability, and whether the formulation is commercially important.

A zinc oxide supplier with proprietary production know-how may have stronger trade-secret protection than patent protection. Calcination conditions, feedstock treatment, milling, surface modification, and impurity-removal processes can be difficult to replicate even when the final chemical identity is public.

How strong is the patent estate for pharmaceutical zinc oxide?

The core patent estate is weak because zinc oxide itself is long established. The strongest protection is likely to reside in downstream formulations and engineered materials rather than the excipient molecule.

IP category	Expected strength	Commercial assessment
Basic zinc oxide composition	Very weak or expired	No meaningful exclusivity
Compendial pharmaceutical grade	No patent exclusivity	Quality and qualification barrier
Nanoparticle formulations	Moderate to strong in selected claims	Higher litigation and regulatory risk
Sunscreen combinations	Moderate	Claims depend on formulation details
Wound-care formulations	Moderate	Often crowded patent field
Manufacturing process	Variable	Trade secrets may matter more
Supplier specifications	Not patent protection	Customer switching barrier

Paragraph IV challenges are relevant only when a marketed finished drug has listed patents covering a zinc oxide formulation or method of use. Zinc oxide itself would not generally create a standalone ANDA exclusivity barrier. Patent risk must therefore be assessed at the finished-product level through FDA Orange Book listings, patent certifications, litigation records, and settlement terms.

What is the Orange Book status of zinc oxide products?

The FDA Orange Book does not create a general exclusivity listing for zinc oxide as an excipient. Zinc oxide appears in numerous OTC and prescription products, but the relevant patent and exclusivity status belongs to the finished drug product and its sponsor.

For an Orange Book analysis, the relevant questions are:

• Is the product approved under an NDA or ANDA?
• Are patents listed for the finished dosage form or method of use?
• Does the product have unexpired regulatory exclusivity?
• Can a generic applicant certify under Paragraph IV?
• Do listed patents cover zinc oxide specifically, or only the broader formulation?
• Has the sponsor filed infringement litigation after receiving a Paragraph IV notice?

The commercial risk is usually lower for a conventional zinc oxide cream than for a new drug-delivery system containing engineered zinc oxide.

What litigation and settlement risks affect zinc oxide products?

Litigation risk is concentrated in four areas:

1. Sunscreen formulations using specific particle sizes, coatings, or dispersion systems.
2. Combination dermatology products.
3. Nanoparticle delivery systems.
4. Finished products with formulation or method-of-use patents.

Supplier-to-supplier litigation over basic pharmaceutical zinc oxide is less likely than disputes involving finished products, trademarks, specifications, supply contracts, or alleged misrepresentation of pharmaceutical grade. Settlement agreements may restrict launch timing, product formulation, manufacturing sources, or geographic commercialization. They may also create authorized-generic arrangements that affect excipient demand.

What manufacturing and supply-chain barriers exist?

The largest barriers are quality consistency and regulatory continuity rather than chemical complexity.

Key risks include:

• Feedstock contamination with heavy metals.
• Variation in surface area and particle-size distribution.
• Batch-to-batch differences in whiteness, dispersion, or rheology.
• Plant shutdowns caused by environmental controls.
• Dependence on Chinese or regional refining capacity.
• Freight disruption and packaging shortages.
• Supplier changes requiring customer notification or regulatory assessment.
• Failure to maintain validated analytical methods.
• Restrictions involving nanoscale zinc oxide.

Pharmaceutical buyers often dual-source only after lengthy qualification. This gives incumbent suppliers meaningful retention even in a commodity market. A supplier disruption can force a finished-product manufacturer to repeat compatibility, stability, microbial, and performance testing.

How does zinc oxide compare with competing excipients?

Zinc oxide competes with titanium dioxide, kaolin, talc, calamine, petrolatum, silicones, barrier polymers, and other mineral or protective ingredients.

Material	Primary advantage	Main limitation
Zinc oxide	Skin protection, opacity, established safety record	Heavy-metal control and regulatory variation
Titanium dioxide	Strong opacity and whiteness	Nanomaterial and inhalation scrutiny
Talc	Low cost and good slip properties	Mineral impurity and contamination concerns
Kaolin	Absorbency and protective effect	Less multifunctional in some formulations
Petrolatum	Strong occlusive barrier	Limited active mineral functionality
Silicone polymers	Elegant sensory profile and water resistance	Higher cost
Barrier polymers	Formulation flexibility	Less established as traditional mineral protectants

Zinc oxide remains competitive because one material can provide opacity, physical barrier properties, and skin-protectant functionality. Its substitution risk is highest in products where color, sensory properties, or regulatory classification are more important than mineral barrier performance.

What generic entry risks exist for zinc oxide products?

Generic entry risk is high for simple topical products with no meaningful formulation differentiation. Barriers rise when a product has:

• A proprietary vehicle.
• Controlled-release or mucoadhesive properties.
• A combination of active ingredients.
• A patented particle-size range.
• Difficult rheology or dispersion requirements.
• Device-like packaging.
• A narrow therapeutic indication.
• Limited qualified zinc oxide suppliers.

For conventional creams and ointments, the excipient itself is unlikely to prevent generic competition. The relevant protection may come from formulation patents, manufacturing process claims, regulatory exclusivity, trademarks, or customer loyalty.

Key Takeaways

• Zinc oxide is a mature pharmaceutical material with stable demand and limited intrinsic patent protection.
• The pharmaceutical-excipient segment is smaller than the industrial zinc oxide market and is not consistently reported separately.
• Revenue growth should be modest, with premiums concentrated in GMP-grade, low-impurity, controlled-particle-size products.
• Zinc prices, energy, freight, and environmental compliance determine supplier margins.
• Topical dermatology, diaper-rash, wound-care, and sunscreen products account for the largest demand base.
• FDA, USP-NF, European Pharmacopoeia, and route-specific regulatory requirements determine market access.
• Orange Book and Paragraph IV risks attach to finished products, not to conventional zinc oxide as a chemical.
• Manufacturing know-how, qualification history, documentation, and supply continuity are more important than composition patents.
• Simple zinc oxide creams face substantial generic-entry risk.
• Engineered particles, nanoparticles, coated materials, and combination formulations carry higher IP and regulatory exposure.

FAQs

Is zinc oxide a pharmaceutical excipient or an active ingredient?

It can be either. In skin-protectant and sunscreen products, zinc oxide may be regulated as an active ingredient. In other formulations, it can function as an excipient, colorant, opacifier, absorbent, or protective additive.

Does zinc oxide have a Drug Master File?

Some suppliers maintain regulatory files or equivalent confidential quality packages, but the existence and scope of a DMF are supplier-specific. A compendial grade does not automatically establish that a supplier has an FDA DMF.

Is nano zinc oxide acceptable for pharmaceutical use?

Acceptance depends on route, particle characteristics, coating, exposure, and finished-product data. Nano zinc oxide receives greater regulatory scrutiny than conventional zinc oxide, particularly for inhalation, systemic exposure, and environmental release.

Can pharmaceutical manufacturers switch zinc oxide suppliers easily?

No. A change may require comparative testing, formulation compatibility work, stability data, supplier qualification, change-control review, and, in some cases, regulatory notification or approval.

What is the main investment risk in the zinc oxide excipient market?

The main risk is margin compression caused by commodity competition and zinc-price volatility. Regulatory changes affecting nanoscale materials, environmental controls, and impurity limits are the principal structural risks.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.

2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2022). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org

3. U.S. Food and Drug Administration. (2024a). Skin protectant drug products for over-the-counter human use. 21 C.F.R. Part 347.

4. U.S. Food and Drug Administration. (2024b). Sunscreen drug products for over-the-counter human use. 21 C.F.R. Part 352.

5. U.S. Food and Drug Administration. (2024c). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/

6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Zinc oxide monograph. U.S. Pharmacopeial Convention.

7. U.S. Food and Drug Administration. (2024d). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/